Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistUnusual buyingEarnings calendarGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreUnusual buyingGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View UPC insider activity ↗

UPCUniverse Pharmaceuticals INC

THE LATEST REPORTED YEAR

The company reported a loss.

$3.67B net loss for the year ended September 30, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$17.86BYear ended September 30, 2025
Profit or loss-$3.67BYear ended September 30, 2025
Cash from the business-$5.05BYear ended September 30, 2025
Total assets$69.3BAs of September 30, 2025
Total liabilities$13.17BAs of September 30, 2025
Cash & equivalents$8.08MAs of September 30, 2021
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$33.23M
2019-09
$30.7M
2020-09
$47.98M
2021-09
$40.14M
2022-09
$32.31B
2023-09
$23.02B
2024-09
$17.86B
2025-09

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
October 1, 2024 – September 30, 2025$17,858,732,000January 29, 202620-F ↗
October 1, 2023 – September 30, 2024$23,024,458,000January 29, 202620-F ↗
October 1, 2022 – September 30, 2023$32,308,735,000January 29, 202620-F ↗
October 1, 2021 – September 30, 2022$40,143,151April 29, 202520-F ↗
October 1, 2020 – September 30, 2021$47,982,031January 30, 202420-F ↗
October 1, 2019 – September 30, 2020$30,703,960February 10, 202320-F ↗
October 1, 2018 – September 30, 2019$33,229,316January 31, 202220-F ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 13, 2026

Response SHA-256: 28b98497960a127fa6db2ca71ea276e531d16187f3f32f46e76ac686f64e2859

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.